RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report

Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While RET fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with TRIM33-RET fusion has not been previously reported. Herein, we presented a case of a 68-year...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tongyi, Wang, Hongwei, Cai, Zhiwei, Zhang, Siqi, Jiang, Chongyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149926/
https://www.ncbi.nlm.nih.gov/pubmed/37139148
http://dx.doi.org/10.3389/fonc.2023.1078076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149926/
https://www.ncbi.nlm.nih.gov/pubmed/37139148
http://dx.doi.org/10.3389/fonc.2023.1078076

Ejemplares similares